Methylhistamine

Inactive metabolites

MAO-B

AUTOCOIDS: Biologic factors that act like local hormones

HISTAMINE:

- Stored in tissue mast cells (skin, lung, GI tract), CSF, & basophils
- Important mediator of immediate allergic & inflammatory reactions, gastric acid secretion, act as NT
- Release:
 - o INDUCED BY: organic bases, Tubocurarine, Succinylcholine, Morphine, Vancomycin
 - O INHIBITED BY:
 - Physiologic Antagonists: β agonists & Epinephrine ↑cAMP & relax smooth muscle (anaphylactic shock, acute allergic reaction)
 - Inhibition of Mast Cell Degranulation: Cromolyn sodium (specifically in *lung*), Nedocromil (in *asthmatics*) inhibit IgE induced ↑Ca²⁺

Histadine -

decarboxylase

| RECEPTORS | RESPONSE | PHYSIOLOGIC ACTION | DRUGS | ADVERSE | |
|-----------|--|---|--|--|--|
| H1 | G _q : ↑IP ₃ , DAG | Smooth muscle, endothelium, brain Nitric Oxide → Vasodilation Contraction of endothelial cells → Edema Smooth muscle contraction → ↑GI motility, Bronchoconstriction, Abortion Sensory nerve endings → Pain + Itching | Blocked by anti-histamines (Pyrilamine) | "TRIPLE RESPONSE": Wheal & Flare 1. Red spot (H ₁) 2. Edematous wheal (H ₁) | |
| H2 | G _S : ↑cAMP | Gastric mucosa, cardiac muscle, mast cells, brain Smooth muscle relaxation ↑Heart rate Gastric parietal ells → ↑CAMP → ↑Ca ²⁺ → ↑gastric acid secretion | Antagonists ↓gastric acid secretion | 3. Red flare (H ₁ + H ₂) Flushing, hypotension, tachycardia, HA, wheals, bronchoconstriction, GI upset | |
| Н3 | G _i : ↓cAMP | CNS: Presynaptic Feedback inhibition modulating release of NTs (hist, NE, serotonin, ACh) Myenteric plexus | | Contraindicated in asthmatics & ulcers | |
| H4 | G _i : ↓cAMP | WBCs & bone marrow Regulates neutrophil release BM, eosinophil shape, & mast cell chemotaxis | Antagonists inhibit mast & eosinophil activity – <i>treat asthma + allergies</i> | | |

Histamine Histamine N-methyl

ANTI-HISTAMINE: H1 Antagonists


| DRUG | MECHANISM | INDICATION | ADVERSE EFFECTS |
|----------------------------|---|--|---|
| 1 st Generation | Reversible, competitive antagonist Lipid Soluble: Rapidly absorbed (oral) Widely distributed: CNS Metabolized by LIVER | Allergic rhinitis, Urticaria Sleeping aids SEDATIVE Nausea & vomiting in pregnancy | Sedation (excitation in children) Anti-muscarinic: Urinary retention, rhinorrhea, blurry vision α-Blocker: orthostatic hypotension, associated mainly with phenothiazines |
| DIPHENHYDRAMINE (Benedryl) | ETHANOLAMINE | Cold medications Adjunct therapy in Parkinson's Motion sickness | - Torsades de pointes QT prolongation |
| CHLORPHENIRAMINE | ALKALAMINE; less sedating | | |
| 2 nd Generation | Reversible, competitive antagonist Do not penetrate CNS – Lack sedative properties Duration: 12-24 hours Metabolized by LIVER | Seasonal allergies | |
| LORATADINE (Claritin) | PIPERIDINES | | |
| CETIRIZINE (Zyrtec) | PIPERAZINE | | |
| FEXOFENADINE (Allegra) | PIPERIDINES | | |

ANTI-HISTAMINE: H2 Antagonists

| DRUG | MECHANISM | INDICATION | ADVERSE EFFECTS |
|----------------------|--|---|--|
| H2 Antagonists | Reversible, competitive antagonist Block acid secretion induced by histamine | PUD, Gastric Ulcers GERD Zollinger-Ellison Syndrome | Diarrhea, Dizziness, Rash, HA Granulocytopenia, thrombocytopenia, neutropenia, aplastic anemia Reversible hepatitis +/- jaundice |
| CIMETIDINE (Tagamet) | Oral absorption → 1 st pass metabolism (liver) Bioavailability only 50%* Secreted by kidneys – ↑ half life In renal failure | | CNS (ELDERLY) — somnolence, confusion, slurred speech, delirium Anti-androgenic: GYNECOMASTIA, ↓ sperm count, GALACTORRHEA INHIBITS CYP450 + ↓ Hepatic blood flow *↑ Warfarin, β-blockers, Ca²+ channel blockers, anti-arrhythmic agents |
| RANITIDINE (Zantac) | | | |
| FAMOTIDINE (Pepcid) | | | No drug interactions © |
| NIZANTIDINE (Axid) | *Bioavailability of 90% | | |

SEROTONIN (5-HT):


- Stored in enterochromaffin cells of GI tract, platelets, & CNS
- Released via mechanical stretch + vagal stimulation + activation of platelets
 - o **INDUCED BY:** Chloroamphetamine
- Key role: regulation of BP, platelet aggregation, headache, & various CNS phenomena



| RECEPTORS | RESPONSE | PHYSIOLOGIC ACTION | DRUGS | ADVERSE |
|-----------|--|---|---------------------------------|--|
| 5-HT1 | G _i : ↓cAMP | 1B/1D: Vasoconstriction in cranial vessels | Sumatriptan: 5-HT1B/1D agonists | SUBENDOCARDIAL FIBROPLASIA: damaged valves + electrical conduction |
| 5-HT2 | G _q : ↑IP ₃ , DAG | 2A: platelet aggregation, contraction of smooth muscle, neuronal excitation, bronchoconstriction (in patients w/ Carcinoid Syndrome) 2B: vascular vasodilation via NO release – may stimulate migraine 2C: modulates mood, feeding, repro, modulation of dopamine & NE release | | from chronic high levels |
| 5-HT3 | Na ⁺ /K ⁺ ligand- gated channel | In area postrema & on vagal afferents & enterochromaffin cells – emesis | | |
| 5-HT7 | G₅: ↑cAMP | Vasodilation of cranial vasculature → migraine | | |

| DRUG | MECHANISM | INDICATION | ADVERSE EFFECTS |
|----------------------------|---|-----------------------------------|--|
| SUMATRIPTAN (Imitrex) | 5HT1 (1B/1D/1F/1E) AGONIST Produces vasoconstriction in cranial vessels & prevents dural extravasation | ACUTE MIGRAINE HEADACHES | Chest pain associated with coronary vasoconstriction Contraindicated in patients w/ coronary ischemia |
| LORCASERIN | Direct acting 5HT2 (2C) AGONIST | WEIGHT LOSS | |
| METHYSERGIDE (Sansert) | 5HT2 (2A/2B/2C) ANTAGONISIT | Prophylaxis: Migraraine | GI, drowsiness, unsteadiness, confusion, hallucination, psychosis INFLAMMATORY FIBROSIS in chronic treatment - Retroperitoneal & pleuropulmonary fibrosis - Cardiac valvular damage |
| CYPROHEPTADINE (Periactin) | 5HT-2A ANTAGONISIT H1 blocker, antimuscarinic, antidepressant | Post-gastrectomy dumping syndrome | |
| ONDANSETRON | 5-HT3 ANTAGONISTS | Anti-emetic in chemotherapy | |
| FENFLURAMINE (MDMA*) | Halogenated amphetamine Directly stimulates 5-HT release | ***BANNED*** APPETITE SUPPRESSANT | Cardiotoxicity |
| FLUOXETINE (Prozac) | SSRI Inhibits 5-HT reuptake | Endogenous depression + OCD | |

Inflammatory mediators




LTB₄ is a **neutrophil** chemotactic agent. **PGI**₂ inhibits platelet aggregation and promotes vasodilation.

Neutrophils arrive "B4" others. Platelet-Gathering Inhibitor.

EICOSANOIDS: Derivatives of Arachidonic Acid

- Not stored; synthesized & released as needed
- Half-lives of PGs are from 30 sec to a few minutes
- HETE = "Hydroxy-Eicosa-Tetra-Enoic" acid



| RECEPTOR | RESPONSE | CARDIO | BLOOD | RENAL | GI | LUNG | UTERUS | CNS |
|--------------------|-------------------------|-----------------|-------------------|------------------------|-----------------------------|-----------------------------------|----------------------|-----------------------|
| PGD | ↑ cAMP | | | | | | | Induces natural sleep |
| PGE | ↑/↓ cAMP | Vasodilator | ↓Platelet aggreg | Diuresis Blocks ADH | ↓Gastric acid ↑Mucus | Relax bronchial muscle | †Uterine muscle tone | ↑Temperature ↑Pain |
| PGE ₂ α | ↑ PLC, Ca ²⁺ | Vasodilator | ↓Platelet aggreg | ↑Renin | ↓Gastric acid | Relax bronchial muscle | ↓Uterine muscle tone | ↑Pain |
| PGI ₂ | ↑ cAMP | Vasoconstrictor | | | Muscle contraction Diarrhea | Contract bronchial muscle | ↑Uterine muscle tone | |
| TXA ₂ | ↑ PLC, Ca ²⁺ | Vasoconstrictor | ↑Platelet aggreg | | | Contract bronchial muscle | ↑Uterine muscle tone | |
| LTD ₄ | ↑ PLC, Ca ²⁺ | ↓Blood volume | ↑Leukocyte aggreg | | Muscle contraction | Contract bronchial muscle + edema | | ↑Pain |

EICOSANOIDS ANALOGS

| DRUG | TYPE | INDICATION | ADVERSE EFFECTS |
|--------------|---|--|--|
| ALPROSTADIL | ALPROSTADIL PGE1 Vasodilator, Inhibits platelet aggregation, Contracts uterine & intestinal smooth muscle, Patency of ductus arteriosis | | Bradycardia, hypotension, fever |
| MISOPROSTOL | PGE1 | Inhibits NSAID-induced gastric ulcers | |
| DINOPROSTONE | DINOPROSTONE PGE2 Promotes uterine contractions & facilitates labor | | Vomiting, diarrhea, fever, bronchoconstriction |
| LATANOPROST | LATANOPROST PGF2α Reduces intraocular pressure – useful in glaucoma | | |
| EPOPROSTANOL | PGI2 | Lowers BP – used in <i>pulmonary HTN</i> | Nausea, HA, hypotension, flushing |

| DRUG | MECHANISM | INDICATION | ADVERSE EFFECTS | |
|--|--|---|--|--|
| COX-1 & COX-2 Inhibitors | Potentiate anticoagulants because of their anti-platelet effects Reduce effects of diuretics & anti-HTN | Anti-inflammatory, Anti-pyretic, Analgesic, Anti-platelet aggregation | Excess PGE ₂ + PGF ₂ $\alpha \rightarrow$ Dysmenorrhea Gastric irritation + bleeding | |
| ASPIRIN: ACETYLSALICYCLIC ACID | IRREVERSIBLY inhibits COX via Acetylation: Synthesis of TXA2 + PG Converts Ω3 fatty acids EPA & DHA into resolvins (anti-inflammatory) | Low Dose ASA ↓risk of death due to thrombosis & MI | Gastric ulceration, Tinnitus (CN8) Chronic use → renal failure REYE SYNDROME in children treated w/ aspirin for a viral infection – acidosis-alkylosis | |
| INDOMETHACIN (Indocin) | Reversibly inhibit COX1 & COX2 blocking PG synthesis | Closes PDA | Interstitial nephritis Gastric ulcer (PGs protect gastric mucosa) | |
| IBUPROFEN (Advil) NAPROXEN (Aleve) | | | Renal ischemia (PGs vasodilate afferent arteriole) | |
| Selective COX-2 | | Arthritis | | |
| Inhibitors | | | | |
| CELECOXIB (Celebrex) | Reversibly inhibits COX2 in <i>inflammatory cells</i> + vascular endothelium | Rheumatoid Arthritis, Osteoarthritis | ↓ Gastric irritation & ulceration (<i>spares COX1</i>) ↑Risk of thrombosis (spares TXA2) | |
| ROFECOXIB (Vioxx) | | | †Risk of MI | |
| COX-3 Inhibitors | | | | |
| ACETAMINOPHEN | Primary site of action: CNS Reversibly inhibits COX | Anti-pyretic & Analgesic (NOT anti-inflammatory) *Used instead of Aspirin in Children w/ viral infection | OVERDOSE : Hepatic necrosis – Metabolite (NAPQI) depletes glutathione & forms toxic byproducts | |
| Anti-Leukotrienes | | | | |
| ZI <u>LEUTON</u> (Zyflo) | Inhibits 5'Lipoxygenase, blocking LT synthesis | ASTHMA, Ulcerative colitis, Allergic rhinitis | | |
| ZAFIR <u>LUCAST</u> MONTE <u>LUCAST</u> | Block LTD4 receptor | Asthma | | |

| PLATELET ACTIVATING FACTOR (PAF) *A physiologic antagonist of PAF effects on platelets would be Prostacyclin | | | | | | | |
|--|---------------------------------|---|--|---------------------------|--|--|--|
| BIOSYNTHESIS DISTRIBUTION MECHANISM OF ACTION INDICATION ADVERSE EFFECTS | | | | | | | |
| Precursor: 1-O-alkyl-2-acyl- | Restricted to blood cells, mast | Stimulates GPCRs, which | Vasodilation | **MOST POTENT ULCEROGENIC | | | |
| glycerophosphocholine | cells, renal medullary cells, | activate phospholipase C, D, A ₂ | ↑Vascular permeability via contraction | SUBSTANCE KNOWN | | | |
| | vascular endothelial cells | | of venular endothelial cells | | | | |
| | | | Stimulates platelet aggregation | | | | |
| | | | Smooth muscle contraction | | | | |